

Anne-SÃ©golÃ¨ne Cottereau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4696279/publications.pdf>

Version: 2024-02-01

47
papers

1,516
citations

516710

16
h-index

330143

37
g-index

48
all docs

48
docs citations

48
times ranked

1317
citing authors

#	ARTICLE	IF	CITATIONS
1	Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. <i>Journal of Clinical Oncology</i> , 2016, 34, 3618-3626.	1.6	231
2	Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3801-3809.	7.0	151
3	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. <i>Blood</i> , 2018, 131, 1456-1463.	1.4	130
4	High total metabolic tumor volume at baseline predicts survival independent of response to therapy. <i>Blood</i> , 2020, 135, 1396-1405.	1.4	119
5	¹⁸ F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome. <i>Journal of Nuclear Medicine</i> , 2020, 61, 40-45.	5.0	109
6	A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies. <i>Journal of Nuclear Medicine</i> , 2022, 63, 172-179.	5.0	96
7	Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT. <i>Annals of Oncology</i> , 2021, 32, 404-411.	1.2	77
8	Deep-Learning ¹⁸ F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 30-36.	5.0	75
9	Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 276-281.	5.0	55
10	Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. <i>Blood</i> , 2018, 131, 2449-2453.	1.4	49
11	Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients. <i>Journal of Nuclear Medicine</i> , 2018, 59, 589-595.	5.0	48
12	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 539-548.	5.2	38
13	Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1267.	2.4	27
14	The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2302.	2.4	25
15	Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2019, 8, 1907.	2.4	20
16	Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1463-1464.	6.4	19
17	Redifferentiating Effect of Larotrectinib in NTRK-Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 594-598.	4.5	19
18	Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interim PET-negative classical Hodgkin Lymphoma patients: A radio-genomic study. <i>Hematological Oncology</i> , 2022, 40, 645-657.	1.7	19

#	ARTICLE	IF	CITATIONS
19	Total tumor burden in lymphoma â€” an evolving strong prognostic parameter. British Journal of Radiology, 2021, 94, 20210448.	2.2	18
20	¹⁸ F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients. Journal of Nuclear Medicine, 2022, 63, 1925-1932.	5.0	18
21	Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2034-2041.	6.4	15
22	Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial.. Journal of Clinical Oncology, 2016, 34, 7509-7509.	1.6	15
23	Adrenal Mass Characterization in the Era of Quantitative Imaging: State of the Art. Cancers, 2022, 14, 569.	3.7	15
24	Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCLâ€™Response. Clinical Cancer Research, 2016, 22, 3414-3415.	7.0	14
25	Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. Cancers, 2021, 13, 2448.	3.7	13
26	New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT. Cancers, 2021, 13, 3998.	3.7	12
27	Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. Haematologica, 2022, 107, 1681-1686.	3.5	12
28	Surgical management of insulinoma over three decades. Hpb, 2021, 23, 1799-1806.	0.3	11
29	Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2020, 9, 1860.	2.4	10
30	Neuroendocrine Carcinomas of the Digestive Tract: What Is New?. Cancers, 2021, 13, 3766.	3.7	10
31	Focal splenic lesions: Imaging spectrum of diseases on CT, MRI and PET/CT. Diagnostic and Interventional Imaging, 2021, 102, 501-513.	3.2	9
32	Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas. Diagnostics, 2022, 12, 417.	2.6	9
33	FDG-PET in PMBCL: which heterogeneity?. Blood, 2018, 132, 117-118.	1.4	4
34	Whole-Body Diffusion-weighted MR Imaging of Iron Deposits in Hodgkin, Follicular, and Diffuse Large B-Cell Lymphoma. Radiology, 2018, 286, 560-567.	7.3	3
35	Visualization of Macroprolactinoma by 18F-Fluorocholine PET/CT in a Patient With Multiple Endocrine Neoplasia Type 1. Journal of the Endocrine Society, 2018, 2, 1170-1172.	0.2	3
36	Total Metabolic Tumor Volume and Tumor Dissemination Are Independent Prognostic Factors in Advanced Hodgkin Lymphoma. Blood, 2021, 138, 880-880.	1.4	3

37	Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups. Blood, 2020, 136, 20-21.	1.4	3
38	18F-fluorocholine PET/CT and conventional imaging in primary hyperparathyroidism. Diagnostic and Interventional Imaging, 2022, 103, 258-265.	3.2	3
39	Brain 18F-FDG, 18F-Florbetaben PET/CT, 123I-FP-CIT SPECT and Cardiac 123I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease. Nuclear Medicine and Molecular Imaging, 2016, 50, 258-260.	1.0	2
40	Successful nelarabine and venetoclax treatment of a relapsed/refractory mediastinal myeloid sarcoma with clonal TCR rearrangement. Anti-Cancer Drugs, 2021, 32, 1118-1122.	1.4	2
41	Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy. Cancers, 2021, 13, 4323.	3.7	2
42	The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World. Blood, 2020, 136, 30-31.	1.4	2
43	PET imaging: back in the game for gastric EMZL?. Blood, 2022, 139, 154-155.	1.4	1
44	Prolonged response to 177Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor. Investigational New Drugs, 2020, 38, 1196-1199.	2.6	0
45	A pheochromocytoma wrapped in an IgG4-related disease. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 929-930.	6.4	0
46	Recurrence of a Pheochromocytoma With TNEM127 Mutation Negative on 18F-FDOPA and 18F-FDG but Positive on 123I-MIBG and 68Ga-DOTATOC Imaging. Clinical Nuclear Medicine, 2022, 47, 251-252.	1.3	0
47	Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge. Blood Cells, Molecules, and Diseases, 2021, 92, 102623.	1.4	0